This clinical trial focuses on patients with invasive breast cancer in its early stages. The study aims to observe the long-term progress of these patients, particularly looking at the frequency, type, and location of the first return of the disease, known as a relapse. The trial includes patients who have participated in previous studies conducted by GEICAM, a research group specializing in breast cancer. The study will gather information on the dates of disease relapse, the occurrence of new primary tumors, and survival rates without events related to cancer.
The trial involves several treatments that have been used in previous studies. These include Xeloda (capecitabine), Gemcitabina Accord (gemcitabine), Paclitaxel Hospira (paclitaxel), Aromasil (exemestane), Faslodex (fulvestrant), Zoladex (goserelin acetate), Abraxane (paclitaxel albumin-bound), TAXOTERE (docetaxel), Myocet (doxorubicin hydrochloride), LAPATINIB, Ofev (nintedanib), Carboplatin, and Herceptin (trastuzumab). These medications are used in various forms, such as tablets, injections, and infusions, to treat breast cancer.
The purpose of this study is to understand how patients with early-stage invasive breast cancer progress over time after receiving these treatments. The study will monitor patients for any signs of the disease returning and will also record survival rates. This information will help researchers and doctors better understand the long-term effects of these treatments and improve future care for breast cancer patients.
Spain 
